LSP to deploy $600M fund to retain larger stakes in early-stage European biotechs
New fund to target €25-€30M per company, with focus on European therapeutics and med-tech companies
LSP has formally closed its sixth fund at $600 million, the largest ever for a European life sciences fund. The firm joins a growing number of European VCs that have announced record fund-raisings in recent years, signaling increased funding opportunities for innovation coming out of
